Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin

Giuseppe Todeschini,Cristina Tecchio,Vittorio Meneghini,G. Pizzolo,Dino Veneri,Roberta Zanotti,M. M. Ricetti,Pietro Solero,Fiorenza Aprili,G. Perona

Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin

1998

Giuseppe Todeschini
Cristina Tecchio
Vittorio Meneghini
G. Pizzolo
Dino Veneri
Roberta Zanotti
M. M. Ricetti
Pietro Solero
Fiorenza Aprili
G. Perona

Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin

Keywords:

Oncology
Cancer research
INDUCTION TREATMENT
Acute lymphocytic leukemia
Intensive Phase
Cytarabine
Daunorubicin
Radiation therapy
Internal medicine
Adult Acute Lymphoblastic Leukemia
Medicine
Surgery
Chemotherapy
Antibiotics
Gastroenterology
Regimen

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations